chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Chest discomfort, Dizziness, Dyspnoea, Fatigue, Heart rate
Clinical narrative: Shortness of breath; Dizzy; Fast heart beat; Pounding heart beat; Slight chest pressure; Fatigue/tiredness; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an intramuscular route of administration in the right arm on 07Oct2021 at 09:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the vaccination. Concomitant medication included metoprolol (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. On 08Oct2021 at 20:00, the patient experienced shortness of breath, dizzy, fast heart beat, pounding heart beat, slight chest pressure and fatigue/tiredness. On the same day at 20:00, the patient underwent heart rate test and the result was fast heartbeat. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events shortness of breath, dizzy, fast heartbeat, pounding heart beat, slight chest pressure and fatigue/tiredness was not resolved at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Heart rate increased, Palpitations
Clinical narrative: Shortness of breath; Dizzy; Fast heart beat; Pounding heart beat; Slight chest pressure; Fatigue/tiredness; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an intramuscular route of administration in the right arm on 07Oct2021 at 09:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the vaccination. Concomitant medication included metoprolol (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. On 08Oct2021 at 20:00, the patient experienced shortness of breath, dizzy, fast heart beat, pounding heart beat, slight chest pressure and fatigue/tiredness. On the same day at 20:00, the patient underwent heart rate test and the result was fast heartbeat. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events shortness of breath, dizzy, fast heartbeat, pounding heart beat, slight chest pressure and fatigue/tiredness was not resolved at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 31.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Cough, Dyspnoea, SARS-CoV-2 test
Clinical narrative: Chills; Shortness of breathe; Cough; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the arm on 07Oct2021 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Oct2021, the patient experienced chills, shortness of breathe and cough. The events resulted in emergency room/department visit or urgent care. On 10Oct2021, the patient underwent nasal swab test for COVID-19 and the result was negative. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events chills, shortness of breathe and cough was not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain in extremity
Clinical narrative: Arm pain; Headache; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2589) via an unspecified route of administration in the left arm on 10Oct2021 at 12:30 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received acetylsalicylic acid (ASPIRIN) on an unknown date and experienced drug allergy. On 10Oct2021 at 16:00, the patient experienced arm pain and headache. The adverse events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events arm pain and headache was resolved on an unknown date in Oct2021 at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea, Fatigue, Immunisation, Myalgia, Off label use
Clinical narrative: The patient received the third/booster dose of BNT162b2; The patient received the third/booster dose of BNT162b2; Injection site pain; Fever; Fatigue; Muscle aches; Difficulty breathing; This is a spontaneous report from a non-contactable consumer, the patient. A 64-year-old male patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0185) via an unspecified route of administration in the left arm on 06Oct2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6178) via an unspecified route of administration in the left arm on 24Feb2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 17Mar2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. On 06Oct2021, the patient experienced injection site pain, fever, fatigue, muscle aches and difficulty breathing. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events injection site pain, fever, fatigue, muscle aches and difficulty breathing was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site pain
Clinical narrative: The patient received the third/booster dose of BNT162b2; The patient received the third/booster dose of BNT162b2; Injection site pain; Fever; Fatigue; Muscle aches; Difficulty breathing; This is a spontaneous report from a non-contactable consumer, the patient. A 64-year-old male patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0185) via an unspecified route of administration in the left arm on 06Oct2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6178) via an unspecified route of administration in the left arm on 24Feb2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 17Mar2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. On 06Oct2021, the patient experienced injection site pain, fever, fatigue, muscle aches and difficulty breathing. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events injection site pain, fever, fatigue, muscle aches and difficulty breathing was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Hypoaesthesia, Muscular weakness
Clinical narrative: Numbness; Swollen arm; Body aches; Weakness of legs; Headaches; Sore arm; Tingling/Pins and needles throughout entire body; Fatigue; Chills; Fever; This is a spontaneous report from a non-contactable consumer, the patient. A 33-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF8839) via an unspecified route of administration in the left arm on 05Oct2021 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included lurasidone hydrochloride (LATUDA), melatonin (MANUFACTURER UNKNOWN) and trazodone hydrochloride (DEPRAX), all for unspecified indication from an unknown date and unknown if ongoing. The patient previously received erythromycin (MANUFACTURER UNKNOWN) and experienced drug allergy. It was not reported if the patient received any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 301308A) via an unspecified route of administration in the left arm on 14Sep2021 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. On 05Oct2021 at 22:00, the patient experienced headaches, sore arm, swollen arm, tingling and numbness, pins and needles throughout entire body, weakness of legs, body aches, fatigue, chills and fever. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department visit or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events headaches, sore arm, swollen arm, tingling and numbness, pins and needles throughout entire body, weakness of legs, body aches, fatigue, chills and fever were resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pain in extremity, Paraesthesia, Peripheral swelling, Pyrexia
Clinical narrative: Numbness; Swollen arm; Body aches; Weakness of legs; Headaches; Sore arm; Tingling/Pins and needles throughout entire body; Fatigue; Chills; Fever; This is a spontaneous report from a non-contactable consumer, the patient. A 33-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF8839) via an unspecified route of administration in the left arm on 05Oct2021 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included lurasidone hydrochloride (LATUDA), melatonin (MANUFACTURER UNKNOWN) and trazodone hydrochloride (DEPRAX), all for unspecified indication from an unknown date and unknown if ongoing. The patient previously received erythromycin (MANUFACTURER UNKNOWN) and experienced drug allergy. It was not reported if the patient received any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 301308A) via an unspecified route of administration in the left arm on 14Sep2021 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. On 05Oct2021 at 22:00, the patient experienced headaches, sore arm, swollen arm, tingling and numbness, pins and needles throughout entire body, weakness of legs, body aches, fatigue, chills and fever. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department visit or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events headaches, sore arm, swollen arm, tingling and numbness, pins and needles throughout entire body, weakness of legs, body aches, fatigue, chills and fever were resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Immunisation, Pain, Rash erythematous
Clinical narrative: 3rd booster dose; Fatigue; Injection site soreness; Full body soreness; Chills; Non-painful and non-itchy red rash on torso and arms; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old male patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an intramuscular route of administration in the right arm on 07Oct2021 at 14:30 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included minerals nos, vitamins nos (CENTRUM), cetirizine hydrochloride (ZYRTEC) and fluticasone propionate (FLONASE); all for unknown indication from unknown date and unknown if ongoing. The patient received influenza vaccine (MANUFACTURER UNKNOWN) via an unspecified route of administration in the left arm on 06Oct2021 for Immunisation within 4 weeks prior to the COVID vaccine. The patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an intramuscular route of administration on 29Jan2021 (at the age of 29-years-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an intramuscular route of administration on 19Feb2021 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. On 07Oct2021, the patient experienced fatigue, injection site soreness, full body soreness, chills and non-painful and non-itchy red rash on torso and arms. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fatigue, injection site soreness, full body soreness, chills and non-painful and non-itchy red rash on torso and arms was resolved on unknown date in Oct2021.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: 3rd booster dose; Fatigue; Injection site soreness; Full body soreness; Chills; Non-painful and non-itchy red rash on torso and arms; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old male patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an intramuscular route of administration in the right arm on 07Oct2021 at 14:30 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included minerals nos, vitamins nos (CENTRUM), cetirizine hydrochloride (ZYRTEC) and fluticasone propionate (FLONASE); all for unknown indication from unknown date and unknown if ongoing. The patient received influenza vaccine (MANUFACTURER UNKNOWN) via an unspecified route of administration in the left arm on 06Oct2021 for Immunisation within 4 weeks prior to the COVID vaccine. The patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an intramuscular route of administration on 29Jan2021 (at the age of 29-years-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an intramuscular route of administration on 19Feb2021 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. On 07Oct2021, the patient experienced fatigue, injection site soreness, full body soreness, chills and non-painful and non-itchy red rash on torso and arms. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fatigue, injection site soreness, full body soreness, chills and non-painful and non-itchy red rash on torso and arms was resolved on unknown date in Oct2021.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Headache, Hyperhidrosis, Immunisation, Off label use
Clinical narrative: Fever; Chills; Sweating / Still sweating three days later; Headache / still headache three days later; The patient received the third/booster dose of BNT162b2; The patient received the third/booster dose of BNT162b2; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old male patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0217) via intramuscular route of administration in the right arm on 08Oct2021 at 10:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included tamsulosin hydrochloride (FLOWMAX), fluticasone furoate, vilanterol trifenatate (BREO ELLIPTA), apixaban (ELIQUIS), paracetamol (TYLENOL) and ibuprofen (ADVIL), all taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL-3247) via intramuscular route of administration in the right arm on 28Jan2021 at 12:00 (at the age of 46-years-old) and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL-3247) via intramuscular route of administration in the right arm on 18Feb2021 at 12:00 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. On 08Oct2021 at 14:00, the patient experienced fever, chills, sweating and headache. On 11Oct 2021, three days later, the patient was still sweating and had headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, sweating, headache and still sweating and headache three days later were resolving at the time of this report.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Fever; Chills; Sweating / Still sweating three days later; Headache / still headache three days later; The patient received the third/booster dose of BNT162b2; The patient received the third/booster dose of BNT162b2; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old male patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0217) via intramuscular route of administration in the right arm on 08Oct2021 at 10:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included tamsulosin hydrochloride (FLOWMAX), fluticasone furoate, vilanterol trifenatate (BREO ELLIPTA), apixaban (ELIQUIS), paracetamol (TYLENOL) and ibuprofen (ADVIL), all taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL-3247) via intramuscular route of administration in the right arm on 28Jan2021 at 12:00 (at the age of 46-years-old) and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL-3247) via intramuscular route of administration in the right arm on 18Feb2021 at 12:00 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. On 08Oct2021 at 14:00, the patient experienced fever, chills, sweating and headache. On 11Oct 2021, three days later, the patient was still sweating and had headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, sweating, headache and still sweating and headache three days later were resolving at the time of this report.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Contusion, Immunisation, Lymphadenopathy, Pain, Pain in extremity
Clinical narrative: Sore and swollen lymph node in arm of vaccine; Sore and swollen lymph node in arm of vaccine; Slight bruising in the armpit 2 days post shot; Body aches and fever 1 day post shot; Body aches and fever 1 day post shot; 3rd Booster dose; This is a spontaneous report from a contactable other healthcare professional, the patient. A 25-year-old non-pregnant female patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Oct2021 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies. The patient did not receive any concomitant medication. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Jan2021 (at the age of 24-years-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Jan2021 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. On 10Oct2021, 1 day post shot, the patient experienced body aches and fever. On 11Oct2021, 2 days post shot, the patient experienced sore and swollen lymph node in the arm of vaccine with slight bruising in the armpit. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore and swollen lymph node in arm of vaccine with slight bruising in the armpit 2 days post shot and body aches and fever 1 day post shot was not resolved at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Sore and swollen lymph node in arm of vaccine; Sore and swollen lymph node in arm of vaccine; Slight bruising in the armpit 2 days post shot; Body aches and fever 1 day post shot; Body aches and fever 1 day post shot; 3rd Booster dose; This is a spontaneous report from a contactable other healthcare professional, the patient. A 25-year-old non-pregnant female patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Oct2021 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies. The patient did not receive any concomitant medication. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Jan2021 (at the age of 24-years-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Jan2021 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. On 10Oct2021, 1 day post shot, the patient experienced body aches and fever. On 11Oct2021, 2 days post shot, the patient experienced sore and swollen lymph node in the arm of vaccine with slight bruising in the armpit. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore and swollen lymph node in arm of vaccine with slight bruising in the armpit 2 days post shot and body aches and fever 1 day post shot was not resolved at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Dry throat
Clinical narrative: Cough; Dry throat; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Oct2021 at 16:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to vaccination, the patient was not diagnosed with COVID -19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 06Oct2021 at 16:30, 30 minutes after shot, the patient experienced cough and dry throat and still coughing on 11Oct2021. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events cough/coughing and dry throat was not resolved at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: Raised red swelling at site with soreness./ Swelling at site resolved after 2days; Raised red swelling at site with soreness.; Raised red swelling at site; Infrequent sharp pains in various joints such as elbow, wrist, kuckles, knee, hip, and thigh areas./ Pain continuing for several days afteronset, especially while lying down or sitting; The patient has received third/booster dose; The patient has received third/booster dose; This is a spontaneous report from a non-contactable consumer, the patient. A 51-year-old male patient received third (booster) dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0186) via an unspecified route of administration in the right arm on 07Oct2021 at 14:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have any allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received influenza vaccine [seqirus - flucelvax Quad Flu-vaccine ;( FLUCELVAX QUADRIVALENT); LAJ-SEQIRUS-FLU ;Lot number: 309614]  in the left arm on 06Oct2021 indicated for immunization, within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318) via an unspecified route of administration in the left arm on 02Mar2021 at 14:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. The patient also previously  received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 23Mar2021 (at the age of 51-years-old) at 14:00 as a single dose for COVID-19 immunisation. On 09Oct2021 at 00:00, two days after injection the patient experienced raised red swelling at site with soreness, Infrequent sharp pains in various joints such as elbow, wrist, knuckles, knee, hip, and thigh areas. Pain had continued for several days after onset, especially while lying down or sitting. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the event raised red swelling at site with soreness was resolved on 11Oct2021. The clinical outcome of the events raised red swelling at site, raised red swelling at site with soreness  and infrequent sharp pains in various joints such as elbow, wrist, knuckles, knee, hip, and thigh areas were unknown at the time of this report.    No follow-up attempts are possible. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Immunisation, SARS-CoV-2 test, Vaccination site pain
Clinical narrative: Mild injection site tenderness; Booster third dose; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FE3590) via an unspecified route of administration in the left arm on 11Oct2021 at 09:30 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included influenza vaccine inact sag 4v (FLUAD QUAD) via unspecified route of administration in the left arm on on 25Sep2021 for immunization and included unspecified multivitamin and ibuprofen (MANUFACTURER UNKNOWN) (over the counter); both for an unknown indication from an unknown date and an unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL8982) via an unspecified route of administration in the left arm on 18Jan2021 at 19:00 (at the age of 68-year-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6201) via an unspecified route of administration in the left arm on 08Feb2021 at 16:00 (at the age of 68-year-old); both as a single dose for COVID-19 immunisation. On 11Oct2021 at 17:00, the patient experienced mild injection site tenderness. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had been tested for COVID-19. On 23Apr2021, the patient underwent COVID-19 virus test via nasal swab and the result was negative. The clinical outcome of the event mild injection site tenderness was not resolved at the time of this report.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Immunisation, Pain in extremity
Clinical narrative: Just slightly sore right arm; "Administration date 06Oct2021, dose number=3"; This is a spontaneous report from a contactable consumer, the patient. A 74-year-old non-pregnant female patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2589) via an unspecified route of administration in the right arm on 06Oct2021 at 11:00, (at the age of 74-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disease (COPD) and breast cancer. The patient was allergic to sulfuric drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other vaccine within four weeks prior to the vaccination which included influenza vaccine (MANUFACTURER UNKNOWN) on 03Oct2021 in the left arm for an unknown indication and unknown if ongoing. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), simvastatin (MANUFACTURER UNKNOWN), fluticasone (MANUFACTURER UNKNOWN) and fluticasone propionate, salmeterol xinafoate (ADVAIR); all from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 09Mar2021 at 14:00 (at the age of 73-years-old) as a single dose for COVID-19 immunisation and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 30Mar2021 at 14:15 (at the age of 73-years-old) as a single dose for COVID-19 immunisation. On 06Oct2021 at 11:00, the patient experienced "administration date 06Oct2021, dose number=3". On 07Oct2021 at 08:00, the patient had just slightly sore right arm. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of event reported. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event just slightly sore right arm was resolved on an unknown date in Oct2021. The clinical outcome of the event "administration date 06Oct2021, dose number=3" was unknown.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Feeling abnormal, Headache, Muscle twitching, Pyrexia
Clinical narrative: Eye twitching; Fast stabbing/sharp pain behind ear (on skull bone); Extreme fever; Chills; Brain fog; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF8839) via an unspecified route of administration in the left arm on 30Sep2021 at 12:15 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included migraine, spinal cord injury and autoimmune disorder. Patient has known latex allergy and fruit allergy (tomatoes). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication was not reported.  The patient previously took amoxicillin (MANUFACTURER UNKNOWN) and clarithromycin (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FD8448) via an unspecified route of administration in the right arm on 07Sep2021 at 12:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. On 01Oct2021, next day of vaccination, the patient experienced extreme fever, chills, brain fog that lasted for approximately 24 hours. On 03Oct2021, 3 days after vaccination the patient experienced eye twitching on and off all day, fast stabbing/sharp pain behind ear (on skull bone) that happened multiple times a day. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme fever, chills and brain fog were resolved within approximately 24 hours of duration on an unknown date of Oct2021. The clinical outcome of the events eye twitching and fast stabbing/sharp pain behind ear (on skull bone) was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Headache, Immunisation, Pain, Pyrexia
Clinical narrative: Administered date: unknown, dose number = 3; Headache; Fever; Body aches and pains; Stomach upset; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had known allergies to latex sensitivity. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On an unknown date, the patient had "administration date unknown, dose number=3". On 08Oct2021 at 17:30, the patient experienced headache, fever, body aches and pains, and stomach upset. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events headache, fever, body aches and pains and stomach upset. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, fever, body aches and pains and stomach upset was recovering at the time of this report. The clinical outcome of the event "administration date unknown, dose number=3" was unknown at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Vertigo
Clinical narrative: Vertigo; Numbness on both hands; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2589) via an unspecified route of administration in the arm left on 08Oct2021 at 16:00 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis. The patient did not have known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included malus spp. vinegar extract (APPLE CIDER VINEGAR), bariatric multivitamin (MANUFACTURER UNKNOWN) and iron (MANUFACTURER UNKNOWN) all from an unknown date for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 3U1358A) via an unspecified route of administration in the left arm on an unknown date in Sep2021 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. On 08Oct2021 at 16:00, the patient experienced vertigo and numbness on both hands. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events vertigo and numbness on both hands was resolved with sequelae on an unknown date in Oct2021.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Amnesia
Clinical narrative: "I" have trouble with memory loss since "I" got the vaccine.; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FC3181) via an unspecified route of administration in the left arm on 29Aug2021 at 11:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FA7485) via an unspecified route of administration in the left arm on 08Aug2021 at 11:00 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. On 30Aug2021 at 00:00, since got the vaccine, the patient had trouble with memory loss. Therapeutic measures were not taken as a result of the reported event. The adverse event did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event trouble with memory loss was not resolved at the time of this report.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Fatigue, Myalgia, Nasopharyngitis, Pain
Clinical narrative: Severe/extreme full-body ache; Muscle pain; Feeling of exertion while sitting still; Feeling of head cold but without excess mucous; Feeling of exertion while sitting still; This is a spontaneous report from a non-contactable consumer, the patient. A 22-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on an unknown date (at the age of 22-years-old) and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date; both as a single dose for COVID-19 immunisation. Medical history included autism, depression, anxiety, in the process of diagnosing something like narcolepsy and known allergies to penicillin. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included bupropion (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date, the patient experienced for 2-3 days starting 12-24 hours after each dose (happened both times), severe/extreme full-body ache and muscle pain, feeling of head cold but without excess mucous and such, and feeling of exertion while sitting still. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events severe/extreme full-body ache and muscle pain, feeling of head cold but without excess mucous and such, and feeling of exertion while sitting still was resolved on an unknown date.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Ear pain, Immunisation, SARS-CoV-2 test
Clinical narrative: Severe shooting stabbing ear pain in my ears every 40-45 seconds.; Patient received a third dose; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received third booster dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 301358A) via an unspecified route of administration in the left arm on 09Oct2021 at 13:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis and allergy to shellfish and iodine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included bupropion (MANUFACTURER UNKNOWN) and alprazolam (MANUFACTURER UNKNOWN); both for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7533) via an unspecified route of administration on 06Apr2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation and a second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0167) via an unspecified route of administration on 27Apr2021 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. On 09Oct2021 at 23:00, about 8 hour after booster shot, the patient had severe shooting stabbing ear pain in ears every 40-45 seconds. The event resulted in emergency room/ department or urgent care. Since the vaccination, the patient had been tested for COVID-19. On 10Oct2021, the patient underwent COVID-19 test via nasal swab and the result was unknown. Therapeutic measures were taken as a result of event and included treatment with fluids, unspecified pain medication. The clinical outcome of the event severe shooting stabbing ear pain in ears every 40-45 seconds was resolved with sequelae on an unknown date in 2021.